Observational Study of METALYSE® in Patients With Acute Myocardial Infarction In Russian Federation

Inclusion Criteria: * onset of symptoms of AMI within 6 hours * on a twelve-lead electrocardiogram (ECG), ST-segment elevation ≥ 0.1 millivolt (mV) in two or more limb leads, or \> 0.2 mV in two or more contiguous precordial leads indicative of AMI, or left bundle-branch block * age ≥ 18 Exclusion Criteria: * significant bleeding disorder at present or within the past 6 months, known hemorrhagic diathesis * patients with current concomitant oral anticoagulant therapy with International Normalised Ratio (INR) \> 1.3 * any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery) * severe uncontrolled arterial hypertension (hypertension defined as blood pressure 180/110 mm Hg (systolic BP \> 180 mm Hg and/or diastolic BP \> 100 mm Hg) on one single reliable measurement during current admission prior to study enrolment * major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this includes any trauma associated with the current AMI), recent trauma to the head or cranium * prolonged or traumatic cardiopulmonary resuscitation (\> 2 minutes) within the past 2 weeks * severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (esophageal varices) and active hepatitis * diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions * active peptic ulceration * arterial aneurysm and known arterial/venous malformation * neoplasm with increased bleeding risk * Acute pericarditis and/or subacute bacterial endocarditis * Acute pancreatitis * hypersensitivity to the active substance tenecteplase and to any of the excipients * use of Abciximab (ReoPro®) or other marketed GPIIb/IIIa antagonists within the preceding 12 hours * any minor head trauma and any other trauma occurring after onset of the current myocardial infarction * any known history of stroke or transient ischemic attack or dementia * pregnancy or lactation, parturition within the previous 30 days. Women of childbearing potential must have a negative pregnancy test * any known active participation in another investigative drug study or device protocol in the past 30 days * previous enrollment in this study * inability to follow protocol and comply with follow-up requirements * any other condition that the investigator feels would place the patient at increased risk if the investigational therapy is initiated